5-aminolevulinic acid 1137
5-fluorouracil 993
5-fluorouracil modulation 896
5-FU 185
5T4 670
ablation 890
abnormal p53 protein expression 946
actigraphy 1202
acute lymphoblastic leukaemia 379
adenocarcinoma 450, 1301
adiponectin 811
adjuvant chemotherapy 627, 884, 896
adjuvant endocrine therapy 1319
adolescence 817
adriamycin 544
advanced breast cancer 515
advanced head and neck cancer 884
advanced pancreatic cancer 185
adverse skeletal events 633
aetiology 842
affinity 1257
Africa 1068
age adjustment 372
age–period–cohort 1077
AKT 1372
all-cause mortality 392
alternative medicine 538
amplification 699
anaemia 224
angiocidin 662
angiogenesis 613, 781, 793, 855, 1128, 1350, 1356
angiotensin I/II 425
angiotensin-converting enzyme 602
anoikis 233
anthropometry 1310
antiangiogenic therapy 876
antibody 1085
antibody response 458
anti-Fas monoclonal antibody 544
anti-late-diarrhoeal program 1341
antisense RNA 216
apoptosis 1, 70, 208, 233, 973, 1157, 1356
array CGH 699, 1191
arterial infusion chemotherapy 557
association 493
ATM heterozygosity 260
aurora 719
basal cell carcinoma 597
Bayesian methods 1077
betel quid 602
biobank 834
biomarkers 735
BK virus 1305
bladder 346
bladder cancer 804, 1182
bleomycin 1209
blood flow 98
body fatness 817
body mass 1057
body mass index 807, 811, 1310
bone metastases 633
bone morphogenetic proteins 850
brain tumours 152, 781
BRCA1 287
BRCA2 287
breast cancer 167, 287, 293, 364, 392, 406, 520, 590, 627, 694, 699, 793, 817, 924, 973, 1005, 1062, 1128, 1152, 1168, 1215, 1295, 1372
breast cancer mortality 392
breast carcinoma 1046
breast neoplasm 582, 1122
breast tumour xenografts 1152
breast-conserving surgery 520, 1122
breastfeeding 379
buccal biopsy 208
burnout 1092
CA19-9 195, 740
cachexia 774
calcium 639, 1364
calcium sensing receptor 1364
calprotectin 639
cancer 478
cancer cachexia 425
cancer of the small intestine 807
cancer of the testis 909
cancer predisposition 260
cancer registries 159, 372
cancer vaccine 1250
capecitabine 510, 1117
carbonic anhydrase IX 1267
carboplatin 1209
carcinogenesis 331
carcinoid 1144
carcinomas 346, 464
cardia 859
case–control 167
case–control study 1057
CD146 793
CD34+ cell 855
CD4 and CD8 lymphocytes 435
cell cycle 939
cervical cancer 376, 862, 1077
cervix 1301
chemoprevention 735
chemoradiotherapy 652, 1117
chemotherapy 29, 54, 224, 233, 279, 302, 483, 740, 744, 909, 977
chemotherapy resistance 510
chemotherapy response 515
child 379
childhood 817
childhood acute lymphoblastic leukaemia 1307
childhood acute myeloid leukaemia 1388
childhood and adolescent cancer 1038
childhood chronic diseases 1053
children 412
chimeric immune receptor 1085
chromosomal radiosensitivity 1038
CIN 248
circadian function 1202
circulating endothelial cells 793
cisplatin 178, 529, 678, 763, 909, 1112, 1117, 1209, 1341, 1356
ckit 107
clinical 890
clinical guidelines 1122
clinical trials 41
clonogenic assay 70
coffee 607
cohort studies 804, 807, 1053, 1310
colon cancer 338, 1356
colon carcinoma 1364
colonic cancer 1062
colorectal adenomas 954
colorectal cancer 1, 399, 510, 744, 799, 896, 1230, 1236
comorbidities 1098
comparison 552
contrast agent 131
C-reactive protein 639
CRM 529
CT antigen 458
cutaneous melanoma 597
CXCR4 924
cyclin A 515
cyclin D1, D2, D3 338
cyclooxygenase-2 954
cytarabine 1388
cytidine deaminase 35
cytochrome P450 973
cytology 1175
cytoskeleton 499
cytotoxic 979
darbepoetin alfa 224
DCE-MRI 979
Decoy receptor 3 544
delay 627
deletion 699
dendritic cell 749
deoxynucleoside analogues 1388
dependence receptor 1
deprivation 622
diabetes mellitus 1310
diagnosis 399, 905
differentiation 338, 450, 1364
disease grade 248
disease-free survival 453
DNA microarray 1182
DNA replication licensing 1295
DNA sequence 1068
DNA vaccination 1250
DNA-PK 1011
docetaxel 173, 999
dose density 7
doxil 46
doxorubicin 89
DRM/Gremlin (CKTSF1B1) 1029
drug delivery 224
drug resistance 483
drug therapy 735
ductal carcinoma in situ 1122
dysadherin 1382
early breast cancer 1319
early-onset breast cancer 260
E-cadherin 1364, 1382
ectodomain shedding 1267
ED1 and ED2 macrophages 435
effectiveness 376
EGFR 107, 124, 915, 1334
EGFRvIII 915
elastase 1024
elderly 770
ELISPOT 248
embryonal carcinoma 1382
EMEA 504
end points 504
endometrial cancer 999, 1062
endostatin 1024
endothelial progenitor cell 855
endothelin-1 98
EORTC 387
ephrin-A1 933
EPIC 1305
epidemiology 811, 838, 842
epidermal growth factor receptor 355
epigenetic inactivation 850
epirubicin 406
EPR effect 678
erbB-2 7
erythropoietin 224, 1350
ETA and ETB receptors distribution 98
ETB agonist IRL 1620 98
etoposide 216, 1209
etoposide phosphate 60
ETS 933
evaluation 862
expression profiling 924
extragonadal germ cell tumour 412
Fab fragment 1257
FAK 694
familial cancer 260
family history 825, 1307
farnesyltransferase inhibitor 1222
Fas 544
Fas ligand 544
FDA 504
feasibility 208
feasibility study 884
febrile neutropenia 1324
fertility 200, 859
fine-needle aspiration 1175
first-line 190
fixed dose rate infusion 35
flk-1 1005
flt-1 1005
fluorouracil 190, 1236
fluvastatin 319
folate 639
follicular neoplasms 1175
follicular thyroid carcinoma (FTC) 144
free fatty acids 639
galectin-3 1175
gastric cancer 688, 986, 1395
gastrocnemius muscle 774
gefitinib 23, 915, 1334
gemcitabine 29, 185, 195, 319, 406, 770, 1112
gemcitabine pharmacokinetic 35
geminin 1295
gene expression 1182, 1277
gene expression profiling 310
gene microarray 483
gene transfer 441
genetic epidemiology 167
genetic instability 719
genetic polymorphism 167
germ-cell tumour 909
gestational trophoblastic neoplasia 620
Gleason grade 1019
glioma 124
glutathione-S-transferase 216
goserelin 647
GOT1 1144
grade of tumour 946
growth arrest 1364
GTPase 499
guideline adherence 520
guidelines 387
haplotypes 954
hazard ratio 607
HB-94 538
head and neck cancer 1117
healing 538
hENT1 1388
hepatocellular carcinoma 458, 557, 607
HER-2 107, 1250
HER-2 overexpression 552
HER3 1334
HHV8 834
HIF 346
HIFU 890
high-dose chemotherapy 412, 620
high-dose palliative radiotherapy 652
high-risk HPV 862
histamine dihydrochloride 757
histology 364, 1046
HL60 human promyelocytic leukaemia 89
Hodgkin’s lymphoma 571
homocysteine 639
Hong Kong 1077
hormone receptor status 946
hormone receptors 364
hormone replacement therapy 582
hormones 200
HPP1 1029
HPV 575, 1068, 1301
HPV16 248
HT29 338
hTERT 116, 152
human 116
human breast cancer 946
human papillomavirus 116, 946
hyaluronidase 81
hypermethylation 1395
hypoxia 224, 346, 1128, 1267, 1356
ID1 933
IFNAR2 557
ifosfamide 178
IL1-RN 493
immortalisation 116
immune response 435
immunofluorescence 834
immunoglobulin 1257
immunohistochemistry (IHC) 107, 144, 453, 464, 478, 688, 1019
immunomodulatory 613
immunoprevention 1250
immunotherapy 458, 670, 749
in vitro fertilisation 1053
infection 379
inflammation 331, 493
inherited predisposition 1038
insulin 639
integrins 167
interferon alpha 441
interleukin-2 273, 757
intermediate and poor prognosis metastatic germ cell tumours 1209
internalisation 1257
interstitial fluid pressure 81
interstitial laser thermotherapy 435
investigation 905
iressa 915
irinotecan 763, 1106, 1230, 1341
isoflavones 15
Japan Collaborative Cohort Study (JACC Study) 607
K-ras 355
k-ras mutation 850
KCNH2 781
KCNH3 781
KDR 1005
keratin 1182
keratinocytic cancer 597
Ki-67 939, 1295
kidney 890
Ktrans 979
Kv 11.1 781
Kv 12.2 781
laser capture microdissection 1301
LDH 273
lenalidomide 613
leptin 811
leukaemia 379, 973
liposomal doxorubicin 81
liquid-based cytology 242, 575
liver 890
local neoplasm recurrence 1122
local vegetarian food 1057
locally advanced rectal cancer 993
LoVo39 338
low-risk 1324
[177Lu-DOTA0-Tyr3]-octreotate 1144
lung adenocarcinoma 355
lung cancer 652, 719, 825, 905, 1329
lymph node metastasis 924, 1128
lymph node micrometastasis 688
lymphangiogenesis 1168
lymphatic invasion 688
lymphatic microvessel density 1168
lymphatic tumour dissemination 1168
lymphatic vessel invasion 1168
lymphoma 1062, 1382
LYVE-1 1168
magnetic resonance imaging 131
major depression 1329
malignant gliomas 152
malignant lymphoma 418
malignant transformation 1285
mammary tumour 1137
mammography 590
mantle cell lymphoma (MCL) 939
marker tumour 387
marketing approval 504
mastectomy 287, 1122
matched case–control study 418
matched pairs 694
maximum likelihood estimation 1077
MCF-7 538, 1005, 1152
MCM 1295
Mcm2 1295
melanoma 216, 933
meningiomas 152
menopausal status 15, 582
meta-analysis 825
metabolism 1011
metachronous colorectal cancer 472
metalloproteases 1267
metaregression 1215
metastases 552
metastasis 1244, 1277
metastatic gastric cancer 190
metastatic germ cell cancer 178
metastatic melanoma 273
metastatic stage 450
methylation 850, 1029
MGMT 529, 1152
microarray 346
microenvironment 302
microsatellite instability 472
microvascular pressure 81
minichromosome maintenance protein 6 (MCM6) 939
minimal residual disease 565
minor depression 1329
mitochondrial DNA 331
mitogen-activated protein kinase 1364
mitomycin C 510
molecular diagnostics 565
monoclonal antibody 131
monocytes 273, 855
mTOR 1372
mts1 protein 1277
mucin 1257
multicellular resistance 302
multidisciplinary teams 977, 1092
multidrug resistance 46, 89
multidrug resistance protein 216
multiple myeloma 70, 613, 834
muscle wasting 425
mutation 915, 1244
myelodysplastic syndromes 613
n-3 fatty acids 639
NADPH cytochrome P450 reductase 89
natural killer cell 441
NCI 387
needle biopsy 478
neoplasia 499, 735
neoplasm 859
nested case–control study 834
neuroblastoma 310
neuroma, acoustic 842
neuronal markers 1197
neurotoxicity 678
neutrophils 273
never-smoker 23
NF-κB 1019, 1285
non-Hodgkin 1062
non-Hodgkin’s lymphoma 159, 811
nonmelanoma skin cancer 597
non-small-cell lung cancer 23, 29, 450, 453, 850, 977, 1098, 1106, 1202, 1334, 1341
non-small-cell lung carcinoma 137
Norway 807
Notch 709
NSCLC 763, 770, 1157
NU7026 1011
nuclear factor κB 70
nude mice 1005
nurse-managed care 41
nutrition 735
obesity 582, 1062, 1310
oesophageal cancer 107, 1112
oestrogen 392, 859
oestrogen plus progestin 392
oestrogen receptor 1046
omega-3 fatty acid 1329
oncofoetal antigen 670
oncofoetal fibronectin mRNA 565
oncology drugs 504
oral antibiotics 1324
oral precancerous lesions 602
oral squamous cell carcinoma 1250
organised programme 376
osteopontin (OPN) 453
ovarian adenoma 709
ovarian cancer 60, 973
ovarian carcinoma 709
ovarian neoplasms 647
ovarian surface epithelium 116
overall survival 453
oxaliplatin 29, 190, 993, 1230
oxidative stress 331, 757
p16 933
p53 242, 355
p53 mutations and ERB-2 expression 946
p53 pathway 124
p70S6K 1372
paclitaxel 178, 1106
paediatric phase I/II 529
palliative 54
palliative benefit 652
pancreas 1024
pancreatic cancer 35, 195, 441, 740, 1062
pancreatic cancer cells 319
pancreatic neoplasms 1310
papillary thyroid carcinoma (PTC) 144
participation in sports 817
pathological complete response 406
patient mortality 946
patient preferences 1319
PDK-1 1372
pegylated liposomal doxorubicin 46
pendrin 144
peritoneal metastasis 986
P-glycoprotein 973
pharmacodynamics 876
pharmacokinetics 876, 1011, 1222
pharmacology 173
phase I clinical trial 876
phase I study 1222
phase II 999, 1112
phosphorylation 1372
photodynamic detection 1137
plasminogen activator inhibitor-1 799
polymeric micelle 678
polymorphisms 954
polyubiquitin 662
portal vein thrombosis 557
predictive factors 7
premenopausal 817
prenatal origin 1307
preoperative chemoradiation 993
prevention 287
primary breast cancer 552
primary chemotherapy 406
primary health care 399
probability 1244
prognosis 7, 124, 137, 152, 450, 515, 627, 740, 838, 933, 1098
prognosis marker 924
prognostic 387
prognostic factors 273
prognostic model 273
progression 242
proliferation 208, 338, 515, 939
prospective studies 986, 1310
prostate 478
prostate cancer 493, 633, 749, 1019, 1285, 1305
prostate neoplasm 1057
proteasome expression 425
protein beam 849
protein degradation 774
proteosome 662
protoporphyrin IX 1137
PSA 1285
PSC 833 46
psychological distress 622
psychological well being 1092
PTEN 124
public health 862
quality of life 200, 1202, 1236
quantitative RT–PCR 144, 799
quiescent 302
Rad51 137
radiation 590, 699
radiotherapy 849, 977
raltitrexed 1230
randomised 279, 757, 862
randomised controlled trial 41
ras effectors 319
RASSF2 1395
rat carcinosarcoma 98
rational 54
Rb1 pathway 124
reactive metabolite(s) 89
real-time PCR 152, 793, 1301
real-time quantitative RT–PCR 986
real-time RT–PCR 565
recurrence of rectal carcinoma 131
redox cycling 89
referral and consultation 399
regional variation 520
regions of imbalance 1191
regulatory 504
relative risk of death 571
REMARK 387
renal cell carcinoma 670, 757
reproductive factors 364
rest/activity function 1202
retinoid 310
retinoid signalling 310
reverse transcription–polymerase chain reaction 688
risk 838
risk assessment 590
RT–PCR 1157
RUNX3 1029
rural 1068
S-1 884
S100A4 1277
salvage chemotherapy 178
salvage therapy 412
scaffold 499
screening 376, 862, 1077
season of diagnosis 571
second primary cancers 159, 418
second-line treatment 763
SEER 1046
seminoma 1382
sentinel node biopsy 520
septin 499
sequential 54
serum phospholipids 1329
sex hormones 859
side effects 744
signal transduction 70
signalling 915
SIL 1068
single-strand conformation polymorphism 355
skin neoplasms 597
sleep quality 1202
small-cell lung cancer 1197
smoking 355, 1310
smoking cessation 1310
SNPs 493, 811
social difficulties 622
somatostatin receptors 1144
soybean products 15
specific induction 694
spheroid 302
squamous cell carcinoma 597
squamous cell head and neck cancer 279
stage 1046
stem cells 719, 855
SUIT-2 1024
superparamagnetic iron oxide 131
surgery 287
surrogate end point 195
surrogate markers 1215
survival 124, 372, 977, 1215
symptoms 905
synchronous colorectal cancer 472
synergism 319
systematic review 293, 825
T cells 248
TACE/ADAM17 1267
Taiwan 1057
tamoxifen 647
taxanes 173, 293
taxol 406
taxotere 173
TβRII 1157
telephone 842
temozolomide 529, 1152
testicular cancer 200, 1307
testicular tumours 1382
testis-specific protein Y-encoded 458
TGFβ 1029
TGF-β1 1157
thalidomide 613
therapy 1144
thrombosis 909
thyroglobulin mRNA 565
thyroid 464, 1175
thyroid cancer 565
thyroid neoplasm 1277
thyroid transcription factor 1 450
timing 627
tissue distribution 81
tissue microarray 137, 478, 1019
TNFα 1024
toenail selenium 804
tolerability 208
topoisomerases 54, 60
topotecan 60
toxicity 1230
transcription factor 1285
transgenic mice 1137
treatment 552
treatment efficacy 744
triacylglycerol 639
trial conclusion 41
Tsp-1 933
tumorigenicity 1157
tumour 302, 979
tumour growth 1350
tumour marker 195
tumour oxygenation 224
tyrosine kinase inhibitor 1334
UbcH10 464
ubiquitin-proteasome proteolysis 774
UFT 770
UK practice 1324
ulcerative colitis 331
unselected 1068
uracil–tegafur 770
urothelial cancer 544
urothelial carcinoma 242
uveal melanoma 1191
vaccination 1068
valspodar 46
variability 208
vascular disruptive agents 979
vascular endothelial growth factor receptor 233
vascular resistance 98
VEGF 107, 924
venous thromboembolism 838
vincristine 1209
viral load sensitivity 575
vitamin D 571
voltage-gated ion channels 1197
waiting times 905
weight gain 582
weight history 582
Western blot 144
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keyword Index for Volume 93. Br J Cancer 93, 1407–1410 (2005). https://doi.org/10.1038/sj.bjc.6602898
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6602898